Member Info for AquaeSulis01

"From past experience interviews have been more of a case of elaborating on factors that have been a bit overlooked by the market (and on here) helping Harry get the message across about the company a gauge to see how confident Harry is and so on.. .anything that helps get he message out there is helpful really."

Spot on Robj. I have seen the interview and the key thing for me is the language, whilst other Junior Pre-production Mining CEO's talk about "if" so and so materialises, Harry is now talking "when"

Thankyou for the responses and agree it does make Samsung a de facto competitor for the current Display market by inclusion of QDs made for their display components by a third party under license for onward sale to their Customers. The answer provided to Q44 by the company whilst technically correct is slightly disingenuous in not acknowledging this.

NGR, are you, or anyone else, able to clarify the following for me please? In the Investor meets Q&A section the following was stated

"Q44: I understand Samsung holds a license for previously disputed NANO patents, including for seeding. That being so, what confidence can NANO shareholders have that NANO can compete with Samsung to develop and bring new products to market? Would NANO derive any income from products if Samsung brings new products to market?

A. Samsung is not a competitor of Nanoco - they do not make QDs. Samsung have a licence to use QDs in Samsung products."

If Samsung do not make QDs then where are they getting the QDs to use in their panels for Customers such as Apple?

"UBI Research analysts at a recent seminar in Seoul had the most details about the future Studio Display model, claiming that Samsung is currently developing 27-inch QD-OLED (Quantum Dot OLED) panels in its A5 manufacturing line. Samsung’s “main customer is expected to be Apple,” according to analysts."

https://www.digitaltrends.com/computing/apple-next-studio-monitor-may-use-qd-oled/

Martinu,

The one part of the business that is doing well is Nutrition which is the area that leanbiome is associated with, As regards the cash position, no issue. From the Results RNS

"Successful exit of loss-making discontinued categories and non-core assets generated a one-off non-cash charge of £26.2m[2], increasing the operating loss to £99.5m (H1 2022: £89.2m). Without this charge, operating loss improved by £15.9m YoY.

· Strong LTM[3] cash performance, ahead of guidance. LTM cash outflow[4] of £20.6m is after £163.1m of capex, mainly in THG Ingenuity. This represents a £350m cash performance improvement on the LTM year on year.

· Strong balance sheet with £563m of cash and available facilities.

· Record H1 THG Nutrition revenue of £340.7m (+2.6%), with adjusted EBITDA of £47.1m (+71.9%)."

Appears a bit superficial and reading the reference to Opti in LGB's Probiotix Health review contains inaccuracies too

"ProBiotix was spun off from Optibiotix in March 2022, and the numbers to its year end in June 2022 were for the three months after the flotation: these amounted to revenues of £306,000 and an operating loss of £256,000, and cash at that time of £2,034,000. It is a finished product company as opposed to Opti which sells ingredients. "

https://www.lgbco.com/quoted-landing-page/new-age-consumer/probiotix/

Hoping the Nahdi sells will help push revenue nearer the £1M mark for H1

Thanks for the explanation qdnano

Well if Apple aren't currently using nanaco Qds for version 1 surely they will be for the later versions if they are relying on Samsung?

"

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.

https://www.ft.com/content/b6f06bde-17b0-4886-b465-b561212c96a9

Apple is working with Korean display makers Samsung and LG on this second-generation headset. In order to drive the price lower, the iPhone maker has explored using other display technologies, including mini-LED, but two people said Apple was insisting on using micro-OLED even for the non-Pro headset, even though all suppliers had so far failed to match its expectations."

https://www.ft.com/content/b6f06bde-17b0-4886-b465-b561212c96a9

Raytheg,

I think you need to appreciate that 95% of the work both TW and Elric do and charge for are connected with researching companies and sharing that knowledge with their subscribers. The former primarily exposes Companies to avoid whilst Elric flags up companies that followers may wish to invest in. I subscribe to both, TW does a daily bearcast that I regularly listen to, not because I may find out something that is not in the public domain or because I am invested in the companies mentioned (and I have never shorted a company in my life) but because I find them entertaining. And that is also the attraction of Elric's interviews with Stuart, I am not expecting to hear something that should be in an RNS but I enjoy the humour and passion displayed by both interviewer and interviewee and that is what I pay for.

As an example, the Croda RNS included the following "Dr Damian Kelly, Vice President Innovation & Technology Development at Croda Europe Ltd, responsible for the project said: "This [SkinBiotix™ programme] continues to be a fascinating project that is heading towards commercialisation and will break new scientific ground in the use of lysated bacteria in the cosmetic industry as a skin care active ingredient."

Dr Kelly added, "We have recently observed some additional unexpected technical benefits during our projected scale-up activities which, if shown to be efficacious through further in-vitro and in-vivo clinical trials, would then offer significant supplementary applications and greater product valorisation as a skin care cosmetic active. We are excited by the findings we have seen thus far and look forward to a long and prosperous relationship with SkinBioTherapeutics.""

Stuart merely added that Dr Kelly is an academic and academics are not usually prone to getting excited about their work so stressed the significance of the comments documented in the RNS.

So as someone who enjoys and looks forward to the podcasts and interviews I say it would be a sad day if my choice to pay and listen to them was denied me.

Hi ddu, I do understand the importance of history and how it can dampen sentiment; the same thing happened at Optibiotix Health which saw the promise of its sweetbiotix product reach heady heights over a pound back in 2018 and has still to launch. Nonetheless, the share price there fell to a point (6p on 28th Jun 2023) where its market cap was less than the value of its owned assets in two other companies it retained shares in, then on 19th July the company issued an RNS Reach that brought to the attention the potential future prospects of its scaled up but still to launch sweetbiotix product to new investors and the share price rocketed to a peak of 39p on the 08th Aug 23 before falling back to its new level of 25p. That company is now fairly valued but does show how quickly things can change, so sometimes best not to look back in anger when the future looks bright.

In fact any positive contract news if presented correctly to attract the attention of new investors as opposed to the stale bulls resident here will see the share price multibag. The M/C is just £56.77M which is less than the net impending Samsung payment of £57.29M at today's exchange rate. Add to that, Cash held at end July 23 was £8.2M, revenue this year is £5.6M and cashburn is just £0.5M per month

I'll class myself as a relatively new investor and I do take a charitable view of the company. what I see is a cash rich low burn company with cutting edge technology, a Market Cap that nowhere near recognises the value of a company that is on the point of taking off in the Infrared Sensor market in addition to the more mature but growing non-cadmium QD display market.

Worth a listen to podcast 5 in the series to appreciate how big the Infra-Red Sensor market is likely to be

https://podcasts.apple.com/us/podcast/qustomdot-radio/id1626235637

Only going by the Nanoco presentation slide that had two companies in the upper right quartile where it was considered well worthwhile evaluating their patents for plagiarism

But it is not just about securing recompense for the past, it will be about securing future royalties going forward now that we have a warchest to pursue companies through the courts if necessary

Everyone seems to have forgotten that a lucrative source of near term income is likely to come from Companies already illegally using Nanaco's technology, with the ability to pay and currently being investigated by Nanaco's hired advisor (2 companies currently in the frame according to Nanaco's July presentation).

Under the terms of the litigation settlement, are Samsumg able to supply their QD-OLED panels developed using Nanaco technology to third parties? Just noticed the following

https://www.quantumdots-info.com/asus-and-philips-launch-new-qd-oled-gaming-monitors

Just a reminder of the relevance of elrico's tight junction research. During SA's recent interview with TW, he mentioned the positive reason for the Croda delay in releasing the ingredient to the end Customers was because following scale-up, increased activities in the closing of Tight Junctions, Transepidermal Water Loss prevention, Prevention of Pathogens, and Restoration of Elasticity were witnessed and hence required scientific clinical measurement to justify an enhanced mark-up of the product. Impact of Tight Junctions and Transepidermal Water Loss prevention explained at the links

https://www.sciencedirect.com/science/article/abs/pii/S0168365916305089

https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/transepidermal-water-loss

Market certainly got this badly wrong if the H&L summary regarding the combined ratio is an indicator of why the share price fell so dramatically

The summaru reads as follows "(Sharecast News) - Insurance group Beazley said it remains on track to hit guidance after delivering record profits in the first half, though its combined ratio jumped.

Pre-tax profit totalled $366.4m in the six months to 30 June, up only slightly from $364.9m a year earlier, despite insurance written premiums rising 13% to $2.92bn.

Beazley said property insurance written premiums jumped 65% while cyber premiums rose 14%.

However, the company saw a sharp rise in insurance service expenses to $2.08bn fro $1.74bn a year earlier.

The combined ratio, a key measure of profitability calculated by dividing incurred losses and expenses by earned premiums (and therefore the lower the better), increased to 84% from 71%.

"We have confidence in the ability of our diversified platform, product and geographic strategy to continue to deliver and look forward to achieving mid-teens growth," said chief executive Adrian Cox.

He reiterated the group's guidance of a full-year combined ratio guidance in the "low eighties".

The eoy 2022 Results RNS 2nd March 2023 stated

"Taking the above into account, we expect to deliver a high-80s combined ratio for 2023 assuming average claims experience. Although significant geopolitical headwinds remain, I believe we are in an excellent position to sustainably grow our company and I am looking forward to all we will achieve together in 2023."

So H1 2023 interims and guidance are unchanged and the already depressed share price warranted an uplift rather than the initial 9% fall first thing.

The frozen dessert looks great as you say Friedman, but for the UK residents to get access to it SOH will need to reduce his margin aspirations so that it can be stocked in the major supermarkets.

Realise it is a long time since you were a teenager Glyn but being anti social and rebellious is part of the make up of teenagers

Looks to me as if the milestones outlined in the Jun 2023 Investor Meets presentation for Q2/3 are being ticked off quite nicely ready for triggering of funds drawdown in Q4 as planned